Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

(2022) Wilfredo F. Garcia-Beltran et al.   CELL

Evolution of antibody immunity to SARS-CoV-2

(2021) Christian Gaebler et al.   NATURE

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

(2021) Saman Saadat et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

(2021) Charlotte Manisty et al.   LANCET

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

(2021) Ezgi Hacisuleyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

(2021) Leonidas Stamatatos et al.   SCIENCE

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

(2021) Catherine J. Reynolds et al.   SCIENCE

Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination

(2021) Rishi R. Goel et al.   Science Immunology

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

(2021) Chang Liu et al.   CELL

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

(2021) Madhumita Shrotri et al.   LANCET

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

(2021) Rebecca P. Payne et al.   CELL

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

(2021) Sara Y Tartof et al.   LANCET

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

(2021) Einav G. Levin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of a Multiplex Tandem PCR (MT-PCR) Assay for the Detection of Emerging SARS-CoV-2 Variants

(2021) Richard Hale et al.   Viruses-Basel

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

(2021) Barak Mizrahi et al.   Nature Communications

Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study

(2021) Ariel Israel et al.   BMJ-British Medical Journal

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern

(2021) Liane Dupont et al.   Nature Microbiology

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

(2020) Philip J. M. Brouwer et al.   SCIENCE

Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020

(2020) Craig P Thompson et al.   Eurosurveillance

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

(2020) Jeffrey Seow et al.   Nature Microbiology

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

(2020) Maheshi N Ramasamy et al.   LANCET